These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33633822)

  • 1. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis.
    Zhang S; Zhou Z; Wang L; Li M; Zhang F; Zeng X
    Ther Adv Chronic Dis; 2021; 12():2040622320976996. PubMed ID: 33633822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Da L; Teng Y; Wang N; Zaguirre K; Liu Y; Qi Y; Song F
    Front Pharmacol; 2019; 10():1671. PubMed ID: 32082164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
    Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.
    Cappelli LC; Gutierrez AK; Bingham CO; Shah AA
    Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Expert Rev Clin Immunol; 2024 Mar; ():1-21. PubMed ID: 38400840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis.
    Veccia A; Kostine M; Tison A; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Caffo O; Paolazzi G; Bortolotti R; Cornec D; Berti A
    Joint Bone Spine; 2022 Jul; 89(4):105403. PubMed ID: 35508288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.
    Bertrand A; Kostine M; Barnetche T; Truchetet ME; Schaeverbeke T
    BMC Med; 2015 Sep; 13():211. PubMed ID: 26337719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.
    Lusa A; Alvarez C; Saxena Beem S; Schwartz TA; Ishizawar R
    BMC Rheumatol; 2022 Nov; 6(1):64. PubMed ID: 36345032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
    Zhong H; Zhou J; Xu D; Zeng X
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
    Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
    Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of rheumatic adverse events of cancer immunotherapy.
    Reid P; Cappelli LC
    Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101805. PubMed ID: 36539321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.
    Dang QM; Watanabe R; Shiomi M; Fukumoto K; Nobashi TW; Okano T; Yamada S; Hashimoto M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.